Oslo, 26 May 2023 - Following the closing of the acceptance period in the
previously announced public offer, Navamedic ASA (OSE: NAVA), a Nordic pharma
company and reliable provider of high-quality products to hospitals and
pharmacies, will become the owner of 96.33 per cent of the share capital and
votes and 93.16 per cent of the series TO 1 warrants ("Warrants") in Sensidose
Aktiebolag ("Sensidose).

This is an important milestone in Navamedic's plan to acquire all outstanding
shares and include Sensidose's product offering in its well proven and highly
scalable market access platform for healthcare products. Navamedic now plans to
initiate a compulsory acquisition of the remaining shares in Sensidose, and to
promote a delisting of the Sensidose shares and Warrants from the Spotlight
Stock Market in Sweden.

"We are excited by the prospect of becoming the owner of Sensidose. Our next
step will be to add Sensidose's unique Parkinson's treatment to our existing
marketing and distribution channels and rapidly ramp up commercialisation
efforts in the Nordics.

We have previously proven our ability to quickly improve product sales through
our agile platform and know-how in the markets where we operate and have already
mapped out several opportunities to increase the sales of Sensidose's treatment
in some of our core markets.

Moving forward, we look forward to cooperating closely with Sensidose and its
highly skilled team to ensure long-term success," said Kathrine Gamborg
Andreassen, CEO of Navamedic.

As of the end of the acceptance period, 25 May 2023, shareholders owning
4,715,283 shares and 1,560,445 Warrants had tendered their shares and Warrants,
corresponding to approximately 39.43 per cent of the share capital and votes and
approximately 68.89 per cent of the Warrants in Sensidose respectively.
Navamedic already holds 56.90 per cent of the outstanding shares and 24.27 per
cent of the Warrants in the company.

The settlement of the shares and Warrants tendered in the offer is expected to
commence on or around 1 June 2023.

Sensidose is a Sweden-based pharmaceutical company that sells drugs in
combination with an innovative device for individual dosing for patients with
advanced Parkinson's disease. Approximately 270 patients are being treated with
Sensidose's medicine in Sweden, Norway and Denmark. Sensidose has already
received market approval in market approval in eight additional countries,
including Finland, whereby the company has been granted reimbursement.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic

Mobile: +47 951 78 680

E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic

Mobile: +47917 62 842

E-mail: lars.hjarrand@navamedic.com

About Navamedic ASA

Navamedic ASA is a Nordic pharma company and reliable provider of high-quality
products, delivered to hospitals and through pharmacies, meeting the specific
needs of patients and consumers by leveraging its highly scalable market access
platform, leading category competence and local knowledge. Navamedic is present
in all the Nordic countries, the Baltics and Benelux, with sales representation
in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on
the Oslo Stock Exchange (ticker: NAVA). For more information, please
visitwww.navamedic.com

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation (MAR) and is subject to the disclosure requirements
pursuant to Section 5-12 the Norwegian Securities Trading Act. The information
was submitted for publication by CFO Lars Hjarrand on 26 May 2023 at 08.00
(CEST).